Steven S. Williamson is the Chief Executive Officer at Pulmonx Corp, a company focused on developing innovative treatments for lung diseases. With an extensive background in the medical device industry, Williamson brings a wealth of experience and expertise to his role at Pulmonx. Prior to joining the company, he held several leadership positions at notable medical technology firms, including serving as the President and CEO of Thoratec Corporation, where he played a pivotal role in the company's growth and eventual acquisition by St. Jude Medical. At Pulmonx, Williamson has been instrumental in guiding the company's strategic direction and overseeing the development and commercialization of its flagship product, the Zephyr Valve, a minimally invasive treatment for severe emphysema. Under his leadership, Pulmonx has achieved significant milestones, including securing regulatory approvals in multiple countries and expanding its global presence. Williamson's strong vision and commitment to improving patient outcomes have been key drivers in establishing Pulmonx as a leader in the field of interventional pulmonology. In addition to his role at Pulmonx, Williamson is actively involved in the broader medical technology community. He serves on the board of directors for several organizations and is a frequent speaker at industry conferences, sharing his insights on the future of healthcare innovation. His dedication to advancing medical technology and improving patient care has earned him recognition as a respected leader in the industry.